Cargando…

Elevated Neutrophil-to-Lymphocyte Ratio Is Associated With Poor Outcomes for Melanoma Patients Treated With PD-1 Inhibitor or Chemotherapy in a Chinese Population

Background: Previous studies have suggested that an elevated pre-treatment neutrophil-to-lymphocyte ratio (NLR) is associated with worse outcomes in patients with a variety of cancers. The purpose of this retrospective analysis is to investigate the prognostic value of the NLR in a Chinese melanoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Yalong, Liao, Daixiang, Mei, Dinglian, Zhang, Yong, Liu, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518238/
https://www.ncbi.nlm.nih.gov/pubmed/33042821
http://dx.doi.org/10.3389/fonc.2020.01752
_version_ 1783587365207408640
author Qi, Yalong
Liao, Daixiang
Mei, Dinglian
Zhang, Yong
Liu, Yang
author_facet Qi, Yalong
Liao, Daixiang
Mei, Dinglian
Zhang, Yong
Liu, Yang
author_sort Qi, Yalong
collection PubMed
description Background: Previous studies have suggested that an elevated pre-treatment neutrophil-to-lymphocyte ratio (NLR) is associated with worse outcomes in patients with a variety of cancers. The purpose of this retrospective analysis is to investigate the prognostic value of the NLR in a Chinese melanoma population. Methods: Melanoma patients were divided into two groups based on pre-treatment NLR values (≥3 vs. <3). Cox proportional hazard regression analysis and the Kaplan-Meier method were employed to study the prognostic role of the NLR for overall survival (OS) and progression-free survival (PFS). Results: A total of 159 melanoma patients were included in this study, including 40 patients treated with PD-1 inhibitor and 119 patients treated with chemotherapy. In the PD-1 inhibitor group, the median OS was 18.0 months in the low NLR subgroup and 5.6 months in the high NLR subgroup; the median PFS was 7.0 and 2.2 months, respectively. In chemotherapy group, the median OS was 23.0 months in the low NLR group and 8.0 months in the high NLR group, and the median PFS was 9.0 and 4.0 months, respectively. Multivariate analysis showed that the NLR was significantly associated with OS and PFS in melanoma patients treated with either PD-1 inhibitor immunotherapy or chemotherapy. Conclusion: In the Chinese population, an elevated NLR was closely related to worse survival in patients with melanoma treated with either PD-1 inhibitor monotherapy or chemotherapy.
format Online
Article
Text
id pubmed-7518238
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75182382020-10-09 Elevated Neutrophil-to-Lymphocyte Ratio Is Associated With Poor Outcomes for Melanoma Patients Treated With PD-1 Inhibitor or Chemotherapy in a Chinese Population Qi, Yalong Liao, Daixiang Mei, Dinglian Zhang, Yong Liu, Yang Front Oncol Oncology Background: Previous studies have suggested that an elevated pre-treatment neutrophil-to-lymphocyte ratio (NLR) is associated with worse outcomes in patients with a variety of cancers. The purpose of this retrospective analysis is to investigate the prognostic value of the NLR in a Chinese melanoma population. Methods: Melanoma patients were divided into two groups based on pre-treatment NLR values (≥3 vs. <3). Cox proportional hazard regression analysis and the Kaplan-Meier method were employed to study the prognostic role of the NLR for overall survival (OS) and progression-free survival (PFS). Results: A total of 159 melanoma patients were included in this study, including 40 patients treated with PD-1 inhibitor and 119 patients treated with chemotherapy. In the PD-1 inhibitor group, the median OS was 18.0 months in the low NLR subgroup and 5.6 months in the high NLR subgroup; the median PFS was 7.0 and 2.2 months, respectively. In chemotherapy group, the median OS was 23.0 months in the low NLR group and 8.0 months in the high NLR group, and the median PFS was 9.0 and 4.0 months, respectively. Multivariate analysis showed that the NLR was significantly associated with OS and PFS in melanoma patients treated with either PD-1 inhibitor immunotherapy or chemotherapy. Conclusion: In the Chinese population, an elevated NLR was closely related to worse survival in patients with melanoma treated with either PD-1 inhibitor monotherapy or chemotherapy. Frontiers Media S.A. 2020-09-11 /pmc/articles/PMC7518238/ /pubmed/33042821 http://dx.doi.org/10.3389/fonc.2020.01752 Text en Copyright © 2020 Qi, Liao, Mei, Zhang and Liu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Qi, Yalong
Liao, Daixiang
Mei, Dinglian
Zhang, Yong
Liu, Yang
Elevated Neutrophil-to-Lymphocyte Ratio Is Associated With Poor Outcomes for Melanoma Patients Treated With PD-1 Inhibitor or Chemotherapy in a Chinese Population
title Elevated Neutrophil-to-Lymphocyte Ratio Is Associated With Poor Outcomes for Melanoma Patients Treated With PD-1 Inhibitor or Chemotherapy in a Chinese Population
title_full Elevated Neutrophil-to-Lymphocyte Ratio Is Associated With Poor Outcomes for Melanoma Patients Treated With PD-1 Inhibitor or Chemotherapy in a Chinese Population
title_fullStr Elevated Neutrophil-to-Lymphocyte Ratio Is Associated With Poor Outcomes for Melanoma Patients Treated With PD-1 Inhibitor or Chemotherapy in a Chinese Population
title_full_unstemmed Elevated Neutrophil-to-Lymphocyte Ratio Is Associated With Poor Outcomes for Melanoma Patients Treated With PD-1 Inhibitor or Chemotherapy in a Chinese Population
title_short Elevated Neutrophil-to-Lymphocyte Ratio Is Associated With Poor Outcomes for Melanoma Patients Treated With PD-1 Inhibitor or Chemotherapy in a Chinese Population
title_sort elevated neutrophil-to-lymphocyte ratio is associated with poor outcomes for melanoma patients treated with pd-1 inhibitor or chemotherapy in a chinese population
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518238/
https://www.ncbi.nlm.nih.gov/pubmed/33042821
http://dx.doi.org/10.3389/fonc.2020.01752
work_keys_str_mv AT qiyalong elevatedneutrophiltolymphocyteratioisassociatedwithpooroutcomesformelanomapatientstreatedwithpd1inhibitororchemotherapyinachinesepopulation
AT liaodaixiang elevatedneutrophiltolymphocyteratioisassociatedwithpooroutcomesformelanomapatientstreatedwithpd1inhibitororchemotherapyinachinesepopulation
AT meidinglian elevatedneutrophiltolymphocyteratioisassociatedwithpooroutcomesformelanomapatientstreatedwithpd1inhibitororchemotherapyinachinesepopulation
AT zhangyong elevatedneutrophiltolymphocyteratioisassociatedwithpooroutcomesformelanomapatientstreatedwithpd1inhibitororchemotherapyinachinesepopulation
AT liuyang elevatedneutrophiltolymphocyteratioisassociatedwithpooroutcomesformelanomapatientstreatedwithpd1inhibitororchemotherapyinachinesepopulation